MedPath
Found 5 clinical trials|View Analysis
Sort by:

Plinabulin iv Solution in Prevention of TAC Induced Neutropenia

Phase 2
Completed
Conditions
Chemotherapy-induced Neutropenia
Interventions
First Posted Date
2020-01-14
Last Posted Date
2020-01-18
Lead Sponsor
BeyondSpring Pharmaceuticals Inc.
Target Recruit Count
115
Registration Number
NCT04227990
Locations
🇨🇳

Cancer Center of Guangzhou Medical University Breast Oncology, Guangzhou, Guangzhou, China

🇨🇳

Fourth Hospital of Hebei Medical University Breast cancer department, Shijiazhuang, Hebei, China

🇨🇳

China-Japan Union Hospital of Jilin University Tumor department of Hematology, Changchun, Jilin, China

and more 8 locations

Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia

Phase 3
Active, not recruiting
Conditions
Chemotherapy-induced Neutropenia
Interventions
First Posted Date
2017-09-27
Last Posted Date
2021-01-15
Lead Sponsor
BeyondSpring Pharmaceuticals Inc.
Target Recruit Count
221
Registration Number
NCT03294577
Locations
🇺🇦

Dnipropetrovsk City Multifunctional Hospital #4 Oncology Department, Dnepropetrovsk, Ukraine

🇺🇦

Prykarpatskiy Regional Oncological Center, Ivano-Frankivs'k, Ukraine

🇺🇦

V.T. Zaycev Institute, Kharkiv, Ukraine

and more 17 locations

Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)

Phase 2
Terminated
Conditions
Neutropenia
Febrile Neutropenia
Breast Cancer
Interventions
First Posted Date
2016-02-18
Last Posted Date
2020-07-31
Lead Sponsor
Asan Medical Center
Target Recruit Count
22
Registration Number
NCT02685111
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

MIBG Scintigraphy and Strain Echocardiography in the Detection of Subclinical Cardiovascular Effects One Year After (Neo)Adjuvant Breast Cancer Treatment With Docetaxel, Doxorubicin and Cyclophosphamide (TAC): a Pilot Study

Conditions
Breast Cancer
First Posted Date
2010-11-23
Last Posted Date
2011-09-12
Lead Sponsor
Radboud University Medical Center
Target Recruit Count
150
Registration Number
NCT01246856
Locations
🇳🇱

University Medical Centre Nijmegen, Nijmegen, Gelderland, Netherlands

Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)

First Posted Date
2005-09-20
Last Posted Date
2015-10-12
Lead Sponsor
Translational Oncology Research International
Target Recruit Count
6
Registration Number
NCT00203372
Locations
🇮🇪

St. James's Hospital, Dublin, Ireland

🇺🇸

UCLA Medical Center, Los Angeles, California, United States

🇺🇸

Wilshire Oncology Medical Group, Inc., Pomona, California, United States

and more 6 locations
© Copyright 2025. All Rights Reserved by MedPath